Resistance to platinum chemotherapy regimens represents a major obstacle in the successful treatment of epithelial ovarian cancer (EOC) patients. Among the molecular mechanism responsible for resistance to platinum, alternative splicing, which is induced upon platinum treatment, can control apoptosis by regulating the expression of apoptotic protein variants with opposite functions. Alterations in alternative splicing are found in tumors and can hinder apoptotic response. In the present study we sequenced SRSF2, a splicing factor that regulates Caspase-8 and Caspase-9 variants, in search of mutations that could possibly explain alternative mechanisms of platinum resistant in EOC
Most women with advanced epithelial ovarian cancers (EOC) will relapse. Currently, there are no pred...
Resistance to platinum-based chemotherapy represents a major clinical challenge for many tumors, inc...
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cance...
AbstractSince its discovery, alternative splicing has been recognized as a powerful way for a cell t...
Epithelial Ovarian Cancer (EOC) is the most lethal gynaecological malignancy due to the advanced sta...
Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. Howe...
Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly sensitive to plati...
© The Author(s), 2016. This article is distributed under the terms of the Creative Commons Attributi...
Most patients with epithelial ovarian cancer (EOC) are still diagnosed in advanced stage disease, ne...
Background: Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to ...
Ovarian cancer has the highest mortality of all gynaecologic malignancies in the developed world. Fo...
Epithelial ovarian cancer (EOC) is the most lethal disease of the female reproductive tract, and alt...
Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, t...
Background: Epithelial ovarian cancer (EOC) is a spectrum of different diseases, which makes their t...
Most patients with epithelial ovarian cancer (EOC) are still diagnosed in advanced stage disease, ne...
Most women with advanced epithelial ovarian cancers (EOC) will relapse. Currently, there are no pred...
Resistance to platinum-based chemotherapy represents a major clinical challenge for many tumors, inc...
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cance...
AbstractSince its discovery, alternative splicing has been recognized as a powerful way for a cell t...
Epithelial Ovarian Cancer (EOC) is the most lethal gynaecological malignancy due to the advanced sta...
Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. Howe...
Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly sensitive to plati...
© The Author(s), 2016. This article is distributed under the terms of the Creative Commons Attributi...
Most patients with epithelial ovarian cancer (EOC) are still diagnosed in advanced stage disease, ne...
Background: Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to ...
Ovarian cancer has the highest mortality of all gynaecologic malignancies in the developed world. Fo...
Epithelial ovarian cancer (EOC) is the most lethal disease of the female reproductive tract, and alt...
Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, t...
Background: Epithelial ovarian cancer (EOC) is a spectrum of different diseases, which makes their t...
Most patients with epithelial ovarian cancer (EOC) are still diagnosed in advanced stage disease, ne...
Most women with advanced epithelial ovarian cancers (EOC) will relapse. Currently, there are no pred...
Resistance to platinum-based chemotherapy represents a major clinical challenge for many tumors, inc...
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cance...